ISPOR 19TH ANNUAL EUROPEAN CONGRESS ISSUE PANEL EXPLORES ISSUE OF ADAPTIVE PATHWAYS AND PATIENT ACCESS

Published Nov 1, 2016
Vienna, Austria—1 November 2016—The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) held an issue panel this afternoon entitled, Adaptive Pathways and Patient Access: Pushing Payer Boundaries or Facilitating New Payment Models? The session took place at the Society’s 19th Annual European Congress in Vienna, Austria.  The issue panel was moderated by Jacoline Bouvy, PhD, Scientific Adviser, National Institute for Health and Care Excellence, London, UK. Speakers for the session included:
  • Hans-Georg Eichler, MD, MSc, Senior Medical Officer, European Medicine Agency, London, UK
  • Ad Schuurman, MSc, MBA, President of MEDEV, Zorginstituut Nederland, Diemen, The Netherlands
  • Claudine Sapede, PharmD, MSc, Global HTA and Payment Policy Lead, F. Hoffmann-La Roche Ltd, Basel, Switzerland
This panel explored the use of adaptive pathways in the development medicines. Speakers noted that adaptive pathways could help patients gain earlier access to promising treatments in areas of high unmet medical needs, but acknowledged that this approach may also have implications for access decisions at the national and regional levels that need to be explored. Jacoline Bouvy, PhD provided an overview of ADAPT SMART, the enabling platform for the coordination of Medicines Adaptive Pathways for Patients (MAPPs) activities. MAPPS seeks to foster access to beneficial treatments for the right patient groups at the earliest appropriate time in the product lifespan in a sustainable fashion. Hans-Georg Eichler, MD, MSc discussed the regulatory viewpoint on adaptive pathways, and Ad Schuurman, MSc, MBA and Claudine Sapede, PharmD, MSc provided perspectives from the payer and industry sectors, respectively. Additional information on the ISPOR 19th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORVienna.

###

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Europe 2025 Plenaries and Speakers Announced

Oct 13, 2025

ISPOR announced details for its ISPOR Europe 2025. The conference is the leading global conference in Europe for health economics and outcomes research (HEOR) and is scheduled for 9-12 November in Glasglow, Scotland, UK with the theme, “Powering Value and Access Through Patient-Centered Collaboration.”
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×